TY - JOUR
T1 - Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
AU - Fernando, Himawan
AU - Duffy, Stephen J.
AU - Low, Ashlea
AU - Dinh, Diem
AU - Adrianopoulos, Nick
AU - Sharma, Anand
AU - Peter, Karlheinz
AU - Stub, Dion
AU - Leong, Kai'En E.
AU - Ajani, Andrew
AU - Clark, David
AU - Freeman, Melanie
AU - Sebastian, Martin
AU - Brennan, Angela
AU - Selkrig, Laura
AU - Reid, Christopher M.
AU - Kaye, David
AU - Oqueli, Ernesto
N1 - Funding Information:
Disclosures: The Melbourne Interventional Group acknowledges funding from Abbott Vascular, Astra-Zeneca, BMS and Pfizer. These companies do not have access to data and do not have the right to review manuscripts or abstracts before publication. The authors have no conflict of interest to declare.
Funding Information:
Funding: Professor Stephen Duffy's work is supported by a National Health and Medical Research Council (NHMRC) of Australia grant (No. 1111170). Professor Reid is supported by a NHMRC Principal Research Fellowship (APP 1136372). A/Prof Stub is supported by a National Heart Foundation of Australia Future Leader Fellowship (reference no. 101908) and a Viertel Foundation Clinical Investigator award.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - The short- and long-term implications of identifying totally occluded culprit coronary arteries (TOCCA) in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) have not been well studied. This study compares clinical characteristics, short- and long-term outcomes of patients with NSTEMI identified with TOCCA to that of patients with non-TOCCA undergoing percutaneous coronary intervention (PCI). We analyzed data from patients with NSTEMI undergoing single-vessel PCI within the Melbourne Interventional Group multi-center registry between 2005 and 2017. Those with TOCCA were compared to those with non-TOCCA. The primary endpoint was 30-day major adverse cardiac events (MACE). Secondary endpoints included 12-month MACE and long-term mortality. A total of 6,829 patients with NSTEMI had single-vessel PCI of which 954 (14%) had TOCCA. Most TOCCA were non-left anterior descending (right coronary artery 39% versus circumflex 33% versus left anterior descending 26%; p <0.001). Cardiogenic shock and left ventricular dysfunction were higher in the TOCCA group, but non-TOCCA patients had more baseline comorbidities. Thirty-day MACE was higher in the TOCCA group (6.7% versus 3.8%; p <0.001). Long-term mortality with an average follow-up of 4.9 years was higher in the non-TOCCA group (12% versus 18%, p <0.01). Multivariable Cox-proportional hazards regression identified TOCCA as an independent predictor of 30-day MACE (HR = 1.93; 95%CI: 1.4-2.6), but not long-term mortality, which was predicted by baseline comorbidities. In conclusion, while patients with NSTEMI with TOCCA undergoing PCI represent a more unstable subgroup early on, long-term outcomes appear more dependent on baseline comorbidities.
AB - The short- and long-term implications of identifying totally occluded culprit coronary arteries (TOCCA) in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) have not been well studied. This study compares clinical characteristics, short- and long-term outcomes of patients with NSTEMI identified with TOCCA to that of patients with non-TOCCA undergoing percutaneous coronary intervention (PCI). We analyzed data from patients with NSTEMI undergoing single-vessel PCI within the Melbourne Interventional Group multi-center registry between 2005 and 2017. Those with TOCCA were compared to those with non-TOCCA. The primary endpoint was 30-day major adverse cardiac events (MACE). Secondary endpoints included 12-month MACE and long-term mortality. A total of 6,829 patients with NSTEMI had single-vessel PCI of which 954 (14%) had TOCCA. Most TOCCA were non-left anterior descending (right coronary artery 39% versus circumflex 33% versus left anterior descending 26%; p <0.001). Cardiogenic shock and left ventricular dysfunction were higher in the TOCCA group, but non-TOCCA patients had more baseline comorbidities. Thirty-day MACE was higher in the TOCCA group (6.7% versus 3.8%; p <0.001). Long-term mortality with an average follow-up of 4.9 years was higher in the non-TOCCA group (12% versus 18%, p <0.01). Multivariable Cox-proportional hazards regression identified TOCCA as an independent predictor of 30-day MACE (HR = 1.93; 95%CI: 1.4-2.6), but not long-term mortality, which was predicted by baseline comorbidities. In conclusion, while patients with NSTEMI with TOCCA undergoing PCI represent a more unstable subgroup early on, long-term outcomes appear more dependent on baseline comorbidities.
UR - http://www.scopus.com/inward/record.url?scp=85111936045&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2021.06.043
DO - 10.1016/j.amjcard.2021.06.043
M3 - Article
C2 - 34362552
AN - SCOPUS:85111936045
SN - 0002-9149
VL - 156
SP - 52
EP - 57
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
ER -